If the COVID-19 crisis represents an unprecedented opportunity for pharma to strengthen its public reputation, it also poses enormous risks if things go wrong, writes Professor Guido Palazzo.
Guido Palazzo
Advertisement
Professor Guido Palazzo is Academic Director at Executive Education HEC.
Articles by Guido Palazzo
Advertisement
Latest Updated Articles
- Why Culture, Ethics, and Compliance Are More Important Than Ever Post-COVID
Published: December 21st 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
3
Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint
4
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
5
